1

1

1

Breakthrough innovation in the fight against pancreatic cancer

Breakthrough innovation in the fight against pancreatic cancer

CC&C is a Medtech start-up. We rely on the latest discoveries in the field of oncology and in particular physical oncology and mechanobiology, to develop a treatment against pancreatic cancer.

Learn more about our technology…

In 2016, we published our Proof of Concept in PlosOne. This experiment validated the action of mechanical stress on a grafted tumor in mice. This is the first time in the world that such a result is obtained on live animals, and not in cell cultures.

Read our article …

Today, our goal is to experimentally validate the action of our device on human pancreatic cancer grafted in mouse pancreas. To do this, we have initiated a partnership in a European consortium around the Bichat Faculty of Medicine in Paris, a world leader in Digestive Oncology.

Learn more about our Proof of Efficacy…

Our medium-term strategy : to finish research within two years and move on to a human prototype, with the goal of a first human experiment in 2023.

Why such a rapid development?

What is Cell Constraint & Cancer ?

of research

raised in 2019

before placing on the market

subscribe to our capital increase

Invest in a breakthrough innovation, unique and patented.

Development faster than a drug.

Latest news from CC&C

Results for the 2nd Quarter 2019

- FOLLOWING THE FAILURE OF OUR APPLICATION FOR A EUROPEAN SUBSIDY, ONE OF OUR SHAREHOLDER COMMITS TO RAISE THE BUDGET FOR PROOF OF EFFICACY - CC & C RECEIVES DELIVERANCE OF ITS PATENT FOR JAPAN AND THE USA On June 20th, we received the notification of rejection of...
Lire la suite

Results for the 1st Quarter 2019

- SHAREHOLDERS TO APPROVE TOD FINANCES' INVESTMENT IN CC&C - CC & C GETS CERTIFICATION BY ITS COMPETITIVENESS CLUSTER We held our General Assembly on May 9th.This was mainly an opportunity to ratify family office “TOD Finances” investment in the company....
Lire la suite

Results for the 4th quarter 2018

- PARTICIPATION IN CC & C - NEWS OF OUR RESEARCH PROJECTS TOD Finances, a french family office, is expected to invest 100,000 euros in our company by the end of February. This excellent news will allow us to hire a new researcher and launch new projects. In...
Lire la suite

5 + 13 =

CELL CONTRAINT & CANCER
le Mas l’Hermite
331 chemin de la Poterie
f13280 Raphèle les Arles

CELL CONTRAINT & CANCER
le Mas l’Hermite
331 chemin de la Poterie
f13280 Raphèle les Arles